Global Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others), By Type, By Regional Outlook and Forecast, 2021 - 2027

The Global Immune Checkpoint Inhibitors Market size is expected to reach $75.9 billion by 2027, rising at a market growth of 16.1% CAGR during the forecast period.

A checkpoint inhibitor is a kind of immunotherapy medicine that works by blocking proteins found on tumor cells that interfere with immune system activity. CTLA-4 (cytotoxic T lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 are all immune checkpoint proteins that are blocked by immune checkpoint inhibitors (programmed death-ligand 1). Immune checkpoint inhibitors work by assisting the immune system in recognizing and attacking cancer cells by targeting checkpoint proteins.

In addition, immune checkpoint inhibitors work by assisting the immune system in recognizing and attacking cancer cells by targeting checkpoint proteins. Due to an increase in demand for optimum therapies for cancer treatment, advantageous payment policies provided by manufacturers and insurance providers in some countries, and an increase in cancer occurrence around the world, the demand for immune checkpoint inhibitors is increasing.

COVID-19 Impact Analysis

COVID-19 Pandemic was first recorded in 2019 in China, after the first appearance, the novel coronavirus rapidly spread across the world and caused severe harm to people as well as businesses. Patients experience a variety of symptoms as a result of this infection, ranging from minor to severe. Dry cough, fever, and exhaustion are some of the most prevalent symptoms. Breathing difficulties or difficulty in breathing, chest pain or pressure, and impairment of speech or movement are all dangerous signs. Moreover, the virus has a significant fatality potential in the geriatric population.

Additionally, COVID-19 has had a negative overall impact on the immune checkpoint inhibitors market, owing to a decrease in the number of cancer patients visiting hospitals and clinics for immune checkpoint inhibitor therapy (ICI), which has resulted in a decrease in demand for immune checkpoint inhibitor products.

Market Growth Factors:

Increasing prevalence of cancer across the world

Lung cancer has a terrible prognosis and is the biggest cause of cancer-related death worldwide. Progression-free survival (PFS) and survival rate are both restricted despite vigorous treatment. Immune checkpoint inhibitors (ICIs) targeting PD1, PDL1, and CTLA-4 have recently been available for a variety of malignancies. ICIs have transformed the treatment of cancer, including lung cancer, and have made a huge breakthrough. However, there are numerous debates about whether patients are best treated with ICIs in terms of monotherapy, combination therapy, and predictive biomarkers.

Immune checkpoint inhibitors have been found to be effective in the treatment of a variety of cancers, including breast, bladder, stomach, colon, liver, cervical, stomach, lung, skin, stomach, and rectal cancer.

Increasing geriatric population across the world

The increasing prevalence of the geriatric population across the world is one of the major concerns of healthcare infrastructures globally. As the age of a person increases, it makes their immune systems more fragile to various kinds of cancers, especially prostate cancer and lung cancer. The geriatric population is majorly more vulnerable to chronic diseases. As per the data shared by the United Nations Organization, in 2019, 703 million people of age 65 or more than that were recorded across the world. Moreover, this number is estimated to reach 1.5 billion by 2050 by the UNO.

Marketing Restraining Factor:

Lack of awareness among people

Cancer is a disease that are of various types, which can begin in practically any organ or tissue of the body and spread to other organs when abnormal cells proliferate uncontrollably, and invade surrounding areas of the body, and/or move to other organs. It is a very fatal disorder that can end up in life losses. One of the major concerns among healthcare practitioners across the world is that a significant population is not fully aware of the prevalence of various types of cancer, which further delays the diagnosis and hence, increases the death rate.

Application Outlook

Based on Application, the market is segmented into Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others. In 2020, the bladder cancer segment registered a significant revenue share in the immune checkpoint inhibitors market. The growth of this segment is increasing as a result of the high prevalence of bladder cancer and advances in diagnostic procedures. In addition, both pembrolizumab and atezolizumab are immune checkpoint inhibitors that have been approved by the FDA to treat patients with metastatic bladder cancer who have progressed after traditional treatments such as chemotherapy medication combinations.

Type Outlook

Based on Type, the market is segmented into PD-1 Inhibitor, PD-L1 Inhibitor, and CTLA-4 Inhibitor. In 2020, The PD-1 inhibitors segment dominated the market by acquiring the largest revenue share of the immune checkpoint inhibitors market. The PD-1 inhibitors are being adopted increasingly due to their efficiency and increase in the prescriptions of nivolumab and pembrolizumab. In addition, pembrolizumab (KEYTRUDA), the first PD-1 inhibitor, has seen increased adoption due to its proven efficacy in treating multiple FDA-approved indications such as melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), and others, all of which are highly prevalent globally, and thus, driving the segment growth.

Immune Checkpoint Inhibitors Market Report Coverage

Report Attribute	Details
Market size value in 2020	USD 29.3 Billion
Market size forecast in 2027	USD 75.9 Billion
Base Year	2020
Historical Period	2017 to 2019
Forecast Period	2021 to 2027
Revenue Growth Rate	CAGR of 16.1% from 2021 to 2027
Number of Pages	185
Number of Tables	283
Report coverage	Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling
Segments covered	Type, Application, Region
Country scope	US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers	Increasing prevalence of cancer across the world Increasing geriatric population across the world
Restraints	Lack of awareness among people

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. Europe acquired a substantial revenue share of the immune checkpoint inhibitors market in 2020. This segment is rapidly flourishing due to the complete availability of immune checkpoint inhibitors around the region. All of the seven immune checkpoint inhibitors viz. pembrolizumab, nivolumab, durvalumab, atezolizumab, avelumab, ipilimumab, and cemiplimab are available in this region.

Free Valuable Insights: Global Immune Checkpoint Inhibitors Market size to reach USD 75.9 Billion by 2027

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Beigene Ltd., Shanghai Junshi Biosciences Co., Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Merck Group (Merck Sharp & Dohme Corp.), Sanofi S.A., Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.

Recent Strategy Deployed in Immune Checkpoint Inhibitors Market

» Partnerships, Collaborations and Agreements:

• Dec-2021: AstraZeneca joined hands with GI Innovation, a bio-venture company based in South Korea. The companies would develop a combined therapy of Imfinzi and GI-101. In addition, the companies would conduct clinical trials evaluating a blend regimen between Imfinzi and GI-101 to diagnose gastric and gastroesophageal junction cancer, triple-negative breast cancer, biliary tract cancer, and lung cancer across Korea, Australia, and the US.
• Dec-2021: Merck entered into a clinical trial collaboration with HiberCell, a clinical-stage biotechnology company. This metastatic breast cancer clinical trial collaboration would evaluate Merck’s anti-PD-1 therapy, KEYTRUDA combined with HiberCell’s odetiglucan, a Dectin-1, pattern recognition receptor agonist.
• Sep-2021: Roche came into a clinical trial collaboration with CG Oncology, a clinical-stage biopharmaceutical company. Under this collaboration, the companies would evaluate CG0070 investigational oncolytic immunotherapy of CG Oncology in combination with atezolizumab anti-PD-L1 therapy of Roche. Moreover, the Phase 1/2 clinical trial would assess the efficiency and safety of this novel immunotherapy combination in patients with a variety of unidentified advanced solid tumors.
• Jun-2021: Merck came into a clinical trial and supply collaboration with Alpine Immune Sciences, a leader in clinical-stage immunotherapy. This collaboration aimed to assess the efficiency and safety of Alpine’s ALPN-202 in combination with Keytruda of Merck.
• May-2021: Sanofi came into a three-year research collaboration with Stanford University School of Medicine. In addition, the entities would focus on enhancing the understanding of inflammation and immunology via open scientific exchange. In addition, the companies would conduct detailed research projects to determine the apparatus of immune-related adverse incidents with immune checkpoint inhibitor therapy with a close emphasis on inflammatory and pneumonitis arthritis intending to discover the role of genomics and pathogenic cell identification.
• Mar-2021: Merck extended its collaboration with Germany, Darmstadt, Genome, and Pfizer. Following this collaboration, the companies would evaluate GEN-001 in combination with avelumab in gastric cancers. Moreover, the research would be initiated with Phase 2a to evaluate the safety and efficacy of the combination utilizing an RP2D, a defined recommended phase 2 dose of GEN-001 combined with avelumab.
• Feb-2021: Merck entered into a clinical trial and supply collaboration with 4D pharma, Darmstadt, Pfizer, and Germany. This collaboration aimed to assess the combination of MRx0518 and bavencio as the first-line diagnosis of locally advanced or metastatic urothelial carcinoma in patients which could not be cured by first-line platinum-containing chemotherapy.
• Jan-2021: Sanofi signed an exclusive global license agreement with Biond Biologics, a privately-held biopharmaceutical company. Under this agreement, the companies aimed to develop and commercialize a humanized IgG4, BND-22 antagonist antibody aiming the Ig-like transcript 2 (ILT2) receptor in development for the diagnosis of solid tumors.
• May-2020: Merck & Co. came into a clinical collaboration with Fujifilm, a Japanese multinational conglomerate. Under this collaboration, the companies would conduct a clinical trial in order to evaluate Merck's Keytruda in combination with Fujifilm’s FF-10832.

» Acquisitions and Mergers:

• Jan-2020: Sanofi completed the acquisition of Synthorx, a clinical-stage biotechnology company. Through this collaboration, Sanofi aimed to strengthen Sanofi's position as a leader in the oncology and immunology sector. Moreover, this acquisition would complement the R&D vision of Sanofi.

» Approvals and Trials:

• Oct-2021: Roche received the US FDA approval for Tecentriq as an adjuvant treatment. This treatment would assist in post-surgery and platinum-based chemotherapy for Stage II-IIIA non-small cell lung cancer in adults with a tumor expressing PD-L1≥1%.
• Jul2021: Merck received the US FDA approval for its KEYTRUDA, an anti-PD-1 therapy. This product aimed to diagnose women with high-risk early-stage triple-negative breast cancer combined with chemotherapy as neoadjuvant treatment. In addition, the new product continued as a single agent as adjuvant treatment, based on Phase 3 KEYNOTE-522 trial, post-surgery.
• Feb-2021: Sanofi got the US FDA approval for Libtayo, a PD-1 inhibitor. This product aimed to diagnose advanced non-small cell lung cancer in patients with tumors comprising higher PD-L1 expression (≥50%). Moreover, Libtayo was combinedly developed by Sanofi and Regeneron.
• May-2020: Bristol Myers Squibb got the US FDA approval for Opdivo 3 mg/kg and Yervoy 1 mg/kg. The new products are approved as the first-line treatment for metastatic non-small cell lung cancer with tumors expressing PD-L1 (≥1%) in patients as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
• Mar-2020: AstraZeneca received the US FDA approval for its Imfinzi, a frontline treatment. This treatment is for adult patients with extensive-stage small-cell lung cancer accompanied by standard-of-care chemotherapies, etoposide, and either cisplatin or carboplatin. In addition, The approval is attributed to positive outcomes from the Phase III CASPIAN trial displaying Imfinzi combined with SoC platinum-etoposidedemonstrated a statistically substantial and clinically relevant enhancement in overall survival and SoC alone.

Scope of the Study

Market Segments Covered in the Report:

By Application

• Lung Cancer
• Bladder Cancer
• Melanoma
• Hodgkin lymphoma
• Others

By Type

• PD-1 Inhibitor
• PD-L1 Inhibitor
• CTLA-4 Inhibitor

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• AstraZeneca PLC
• Beigene Ltd.
• Shanghai Junshi Biosciences Co., Ltd.
• Bristol Myers Squibb Company
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Merck Group (Merck Sharp & Dohme Corp.)
• Sanofi S.A.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Immune Checkpoint Inhibitors Market, by Application
1.4.2 Global Immune Checkpoint Inhibitors Market, by Type
1.4.3 Global Immune Checkpoint Inhibitors Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, May – 2021, Dec) Leading Players

Chapter 4. Global Immune Checkpoint Inhibitors Market by Application
4.1 Global Lung Cancer Market by Region
4.2 Global Bladder Cancer Market by Region
4.3 Global Melanoma Market by Region
4.4 Global Hodgkin lymphoma Market by Region
4.5 Global Other Application Market by Region

Chapter 5. Global Immune Checkpoint Inhibitors Market by Type
5.1 Global PD-1 Inhibitor Market by Region
5.2 Global PD-L1 Inhibitor Market by Region
5.3 Global CTLA-4 Inhibitor Market by Region

Chapter 6. Global Immune Checkpoint Inhibitors Market by Region
6.1 North America Immune Checkpoint Inhibitors Market
6.1.1 North America Immune Checkpoint Inhibitors Market by Application
6.1.1.1 North America Lung Cancer Market by Country
6.1.1.2 North America Bladder Cancer Market by Country
6.1.1.3 North America Melanoma Market by Country
6.1.1.4 North America Hodgkin lymphoma Market by Country
6.1.1.5 North America Other Application Market by Country
6.1.2 North America Immune Checkpoint Inhibitors Market by Type
6.1.2.1 North America PD-1 Inhibitor Market by Country
6.1.2.2 North America PD-L1 Inhibitor Market by Country
6.1.2.3 North America CTLA-4 Inhibitor Market by Country
6.1.3 North America Immune Checkpoint Inhibitors Market by Country
6.1.3.1 US Immune Checkpoint Inhibitors Market
6.1.3.1.1 US Immune Checkpoint Inhibitors Market by Application
6.1.3.1.2 US Immune Checkpoint Inhibitors Market by Type
6.1.3.2 Canada Immune Checkpoint Inhibitors Market
6.1.3.2.1 Canada Immune Checkpoint Inhibitors Market by Application
6.1.3.2.2 Canada Immune Checkpoint Inhibitors Market by Type
6.1.3.3 Mexico Immune Checkpoint Inhibitors Market
6.1.3.3.1 Mexico Immune Checkpoint Inhibitors Market by Application
6.1.3.3.2 Mexico Immune Checkpoint Inhibitors Market by Type
6.1.3.4 Rest of North America Immune Checkpoint Inhibitors Market
6.1.3.4.1 Rest of North America Immune Checkpoint Inhibitors Market by Application
6.1.3.4.2 Rest of North America Immune Checkpoint Inhibitors Market by Type
6.2 Europe Immune Checkpoint Inhibitors Market
6.2.1 Europe Immune Checkpoint Inhibitors Market by Application
6.2.1.1 Europe Lung Cancer Market by Country
6.2.1.2 Europe Bladder Cancer Market by Country
6.2.1.3 Europe Melanoma Market by Country
6.2.1.4 Europe Hodgkin lymphoma Market by Country
6.2.1.5 Europe Other Application Market by Country
6.2.2 Europe Immune Checkpoint Inhibitors Market by Type
6.2.2.1 Europe PD-1 Inhibitor Market by Country
6.2.2.2 Europe PD-L1 Inhibitor Market by Country
6.2.2.3 Europe CTLA-4 Inhibitor Market by Country
6.2.3 Europe Immune Checkpoint Inhibitors Market by Country
6.2.3.1 Germany Immune Checkpoint Inhibitors Market
6.2.3.1.1 Germany Immune Checkpoint Inhibitors Market by Application
6.2.3.1.2 Germany Immune Checkpoint Inhibitors Market by Type
6.2.3.2 UK Immune Checkpoint Inhibitors Market
6.2.3.2.1 UK Immune Checkpoint Inhibitors Market by Application
6.2.3.2.2 UK Immune Checkpoint Inhibitors Market by Type
6.2.3.3 France Immune Checkpoint Inhibitors Market
6.2.3.3.1 France Immune Checkpoint Inhibitors Market by Application
6.2.3.3.2 France Immune Checkpoint Inhibitors Market by Type
6.2.3.4 Russia Immune Checkpoint Inhibitors Market
6.2.3.4.1 Russia Immune Checkpoint Inhibitors Market by Application
6.2.3.4.2 Russia Immune Checkpoint Inhibitors Market by Type
6.2.3.5 Spain Immune Checkpoint Inhibitors Market
6.2.3.5.1 Spain Immune Checkpoint Inhibitors Market by Application
6.2.3.5.2 Spain Immune Checkpoint Inhibitors Market by Type
6.2.3.6 Italy Immune Checkpoint Inhibitors Market
6.2.3.6.1 Italy Immune Checkpoint Inhibitors Market by Application
6.2.3.6.2 Italy Immune Checkpoint Inhibitors Market by Type
6.2.3.7 Rest of Europe Immune Checkpoint Inhibitors Market
6.2.3.7.1 Rest of Europe Immune Checkpoint Inhibitors Market by Application
6.2.3.7.2 Rest of Europe Immune Checkpoint Inhibitors Market by Type
6.3 Asia Pacific Immune Checkpoint Inhibitors Market
6.3.1 Asia Pacific Immune Checkpoint Inhibitors Market by Application
6.3.1.1 Asia Pacific Lung Cancer Market by Country
6.3.1.2 Asia Pacific Bladder Cancer Market by Country
6.3.1.3 Asia Pacific Melanoma Market by Country
6.3.1.4 Asia Pacific Hodgkin lymphoma Market by Country
6.3.1.5 Asia Pacific Other Application Market by Country
6.3.2 Asia Pacific Immune Checkpoint Inhibitors Market by Type
6.3.2.1 Asia Pacific PD-1 Inhibitor Market by Country
6.3.2.2 Asia Pacific PD-L1 Inhibitor Market by Country
6.3.2.3 Asia Pacific CTLA-4 Inhibitor Market by Country
6.3.3 Asia Pacific Immune Checkpoint Inhibitors Market by Country
6.3.3.1 China Immune Checkpoint Inhibitors Market
6.3.3.1.1 China Immune Checkpoint Inhibitors Market by Application
6.3.3.1.2 China Immune Checkpoint Inhibitors Market by Type
6.3.3.2 Japan Immune Checkpoint Inhibitors Market
6.3.3.2.1 Japan Immune Checkpoint Inhibitors Market by Application
6.3.3.2.2 Japan Immune Checkpoint Inhibitors Market by Type
6.3.3.3 India Immune Checkpoint Inhibitors Market
6.3.3.3.1 India Immune Checkpoint Inhibitors Market by Application
6.3.3.3.2 India Immune Checkpoint Inhibitors Market by Type
6.3.3.4 South Korea Immune Checkpoint Inhibitors Market
6.3.3.4.1 South Korea Immune Checkpoint Inhibitors Market by Application
6.3.3.4.2 South Korea Immune Checkpoint Inhibitors Market by Type
6.3.3.5 Singapore Immune Checkpoint Inhibitors Market
6.3.3.5.1 Singapore Immune Checkpoint Inhibitors Market by Application
6.3.3.5.2 Singapore Immune Checkpoint Inhibitors Market by Type
6.3.3.6 Malaysia Immune Checkpoint Inhibitors Market
6.3.3.6.1 Malaysia Immune Checkpoint Inhibitors Market by Application
6.3.3.6.2 Malaysia Immune Checkpoint Inhibitors Market by Type
6.3.3.7 Rest of Asia Pacific Immune Checkpoint Inhibitors Market
6.3.3.7.1 Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Application
6.3.3.7.2 Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Type
6.4 LAMEA Immune Checkpoint Inhibitors Market
6.4.1 LAMEA Immune Checkpoint Inhibitors Market by Application
6.4.1.1 LAMEA Lung Cancer Market by Country
6.4.1.2 LAMEA Bladder Cancer Market by Country
6.4.1.3 LAMEA Melanoma Market by Country
6.4.1.4 LAMEA Hodgkin lymphoma Market by Country
6.4.1.5 LAMEA Other Application Market by Country
6.4.2 LAMEA Immune Checkpoint Inhibitors Market by Type
6.4.2.1 LAMEA PD-1 Inhibitor Market by Country
6.4.2.2 LAMEA PD-L1 Inhibitor Market by Country
6.4.2.3 LAMEA CTLA-4 Inhibitor Market by Country
6.4.3 LAMEA Immune Checkpoint Inhibitors Market by Country
6.4.3.1 Brazil Immune Checkpoint Inhibitors Market
6.4.3.1.1 Brazil Immune Checkpoint Inhibitors Market by Application
6.4.3.1.2 Brazil Immune Checkpoint Inhibitors Market by Type
6.4.3.2 Argentina Immune Checkpoint Inhibitors Market
6.4.3.2.1 Argentina Immune Checkpoint Inhibitors Market by Application
6.4.3.2.2 Argentina Immune Checkpoint Inhibitors Market by Type
6.4.3.3 UAE Immune Checkpoint Inhibitors Market
6.4.3.3.1 UAE Immune Checkpoint Inhibitors Market by Application
6.4.3.3.2 UAE Immune Checkpoint Inhibitors Market by Type
6.4.3.4 Saudi Arabia Immune Checkpoint Inhibitors Market
6.4.3.4.1 Saudi Arabia Immune Checkpoint Inhibitors Market by Application
6.4.3.4.2 Saudi Arabia Immune Checkpoint Inhibitors Market by Type
6.4.3.5 South Africa Immune Checkpoint Inhibitors Market
6.4.3.5.1 South Africa Immune Checkpoint Inhibitors Market by Application
6.4.3.5.2 South Africa Immune Checkpoint Inhibitors Market by Type
6.4.3.6 Nigeria Immune Checkpoint Inhibitors Market
6.4.3.6.1 Nigeria Immune Checkpoint Inhibitors Market by Application
6.4.3.6.2 Nigeria Immune Checkpoint Inhibitors Market by Type
6.4.3.7 Rest of LAMEA Immune Checkpoint Inhibitors Market
6.4.3.7.1 Rest of LAMEA Immune Checkpoint Inhibitors Market by Application
6.4.3.7.2 Rest of LAMEA Immune Checkpoint Inhibitors Market by Type

Chapter 7. Company Profiles
7.1 AstraZeneca PLC
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Approvals and Trials:
7.2 Beigene Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 Shanghai Junshi Biosciences Co., Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.4 Bristol Myers Squibb Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 GlaxoSmithKline PLC (GSK)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Eli Lilly and Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.7 Merck Group (Merck Sharp & Dohme Corp.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Sanofi S.A.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.8.5.2 Approvals and Trials:
7.8.5.3 Acquisition and Mergers:
7.9 Merck & Co., Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals and Trials:
7.10. F. Hoffmann-La Roche Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.6 Partnerships, Collaborations and Agreements:
7.10.6.1 Approvals and Trials:

TABLE 1 Global Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 2 Global Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Immune Checkpoint Inhibitors Market
TABLE 4 Acquisition and Mergers– Immune Checkpoint Inhibitors Market
TABLE 5 Approvals and Trials– Immune Checkpoint Inhibitors Market
TABLE 6 Global Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 7 Global Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 8 Global Lung Cancer Market by Region, 2017 - 2020, USD Million
TABLE 9 Global Lung Cancer Market by Region, 2021 - 2027, USD Million
TABLE 10 Global Bladder Cancer Market by Region, 2017 - 2020, USD Million
TABLE 11 Global Bladder Cancer Market by Region, 2021 - 2027, USD Million
TABLE 12 Global Melanoma Market by Region, 2017 - 2020, USD Million
TABLE 13 Global Melanoma Market by Region, 2021 - 2027, USD Million
TABLE 14 Global Hodgkin lymphoma Market by Region, 2017 - 2020, USD Million
TABLE 15 Global Hodgkin lymphoma Market by Region, 2021 - 2027, USD Million
TABLE 16 Global Other Application Market by Region, 2017 - 2020, USD Million
TABLE 17 Global Other Application Market by Region, 2021 - 2027, USD Million
TABLE 18 Global Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 19 Global Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 20 Global PD-1 Inhibitor Market by Region, 2017 - 2020, USD Million
TABLE 21 Global PD-1 Inhibitor Market by Region, 2021 - 2027, USD Million
TABLE 22 Global PD-L1 Inhibitor Market by Region, 2017 - 2020, USD Million
TABLE 23 Global PD-L1 Inhibitor Market by Region, 2021 - 2027, USD Million
TABLE 24 Global CTLA-4 Inhibitor Market by Region, 2017 - 2020, USD Million
TABLE 25 Global CTLA-4 Inhibitor Market by Region, 2021 - 2027, USD Million
TABLE 26 Global Immune Checkpoint Inhibitors Market by Region, 2017 - 2020, USD Million
TABLE 27 Global Immune Checkpoint Inhibitors Market by Region, 2021 - 2027, USD Million
TABLE 28 North America Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 29 North America Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 30 North America Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 31 North America Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 32 North America Lung Cancer Market by Country, 2017 - 2020, USD Million
TABLE 33 North America Lung Cancer Market by Country, 2021 - 2027, USD Million
TABLE 34 North America Bladder Cancer Market by Country, 2017 - 2020, USD Million
TABLE 35 North America Bladder Cancer Market by Country, 2021 - 2027, USD Million
TABLE 36 North America Melanoma Market by Country, 2017 - 2020, USD Million
TABLE 37 North America Melanoma Market by Country, 2021 - 2027, USD Million
TABLE 38 North America Hodgkin lymphoma Market by Country, 2017 - 2020, USD Million
TABLE 39 North America Hodgkin lymphoma Market by Country, 2021 - 2027, USD Million
TABLE 40 North America Other Application Market by Country, 2017 - 2020, USD Million
TABLE 41 North America Other Application Market by Country, 2021 - 2027, USD Million
TABLE 42 North America Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 43 North America Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 44 North America PD-1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 45 North America PD-1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 46 North America PD-L1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 47 North America PD-L1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 48 North America CTLA-4 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 49 North America CTLA-4 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 50 North America Immune Checkpoint Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 51 North America Immune Checkpoint Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 52 US Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 53 US Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 54 US Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 55 US Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 56 US Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 57 US Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 58 Canada Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 59 Canada Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 60 Canada Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 61 Canada Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 62 Canada Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 63 Canada Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 64 Mexico Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 65 Mexico Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 66 Mexico Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 67 Mexico Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 68 Mexico Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 69 Mexico Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 70 Rest of North America Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 71 Rest of North America Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 72 Rest of North America Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 73 Rest of North America Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 74 Rest of North America Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 75 Rest of North America Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 76 Europe Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 77 Europe Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 78 Europe Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 79 Europe Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 80 Europe Lung Cancer Market by Country, 2017 - 2020, USD Million
TABLE 81 Europe Lung Cancer Market by Country, 2021 - 2027, USD Million
TABLE 82 Europe Bladder Cancer Market by Country, 2017 - 2020, USD Million
TABLE 83 Europe Bladder Cancer Market by Country, 2021 - 2027, USD Million
TABLE 84 Europe Melanoma Market by Country, 2017 - 2020, USD Million
TABLE 85 Europe Melanoma Market by Country, 2021 - 2027, USD Million
TABLE 86 Europe Hodgkin lymphoma Market by Country, 2017 - 2020, USD Million
TABLE 87 Europe Hodgkin lymphoma Market by Country, 2021 - 2027, USD Million
TABLE 88 Europe Other Application Market by Country, 2017 - 2020, USD Million
TABLE 89 Europe Other Application Market by Country, 2021 - 2027, USD Million
TABLE 90 Europe Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 91 Europe Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 92 Europe PD-1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 93 Europe PD-1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 94 Europe PD-L1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 95 Europe PD-L1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 96 Europe CTLA-4 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 97 Europe CTLA-4 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 98 Europe Immune Checkpoint Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 99 Europe Immune Checkpoint Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 100 Germany Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 101 Germany Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 102 Germany Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 103 Germany Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 104 Germany Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 105 Germany Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 106 UK Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 107 UK Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 108 UK Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 109 UK Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 110 UK Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 111 UK Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 112 France Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 113 France Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 114 France Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 115 France Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 116 France Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 117 France Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 118 Russia Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 119 Russia Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 120 Russia Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 121 Russia Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 122 Russia Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 123 Russia Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 124 Spain Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 125 Spain Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 126 Spain Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 127 Spain Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 128 Spain Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 129 Spain Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 130 Italy Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 131 Italy Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 132 Italy Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 133 Italy Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 134 Italy Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 135 Italy Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 136 Rest of Europe Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 137 Rest of Europe Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 138 Rest of Europe Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 139 Rest of Europe Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 140 Rest of Europe Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 141 Rest of Europe Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 142 Asia Pacific Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 143 Asia Pacific Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 144 Asia Pacific Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 145 Asia Pacific Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 146 Asia Pacific Lung Cancer Market by Country, 2017 - 2020, USD Million
TABLE 147 Asia Pacific Lung Cancer Market by Country, 2021 - 2027, USD Million
TABLE 148 Asia Pacific Bladder Cancer Market by Country, 2017 - 2020, USD Million
TABLE 149 Asia Pacific Bladder Cancer Market by Country, 2021 - 2027, USD Million
TABLE 150 Asia Pacific Melanoma Market by Country, 2017 - 2020, USD Million
TABLE 151 Asia Pacific Melanoma Market by Country, 2021 - 2027, USD Million
TABLE 152 Asia Pacific Hodgkin lymphoma Market by Country, 2017 - 2020, USD Million
TABLE 153 Asia Pacific Hodgkin lymphoma Market by Country, 2021 - 2027, USD Million
TABLE 154 Asia Pacific Other Application Market by Country, 2017 - 2020, USD Million
TABLE 155 Asia Pacific Other Application Market by Country, 2021 - 2027, USD Million
TABLE 156 Asia Pacific Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 157 Asia Pacific Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 158 Asia Pacific PD-1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 159 Asia Pacific PD-1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 160 Asia Pacific PD-L1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 161 Asia Pacific PD-L1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 162 Asia Pacific CTLA-4 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 163 Asia Pacific CTLA-4 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 164 Asia Pacific Immune Checkpoint Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 165 Asia Pacific Immune Checkpoint Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 166 China Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 167 China Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 168 China Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 169 China Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 170 China Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 171 China Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 172 Japan Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 173 Japan Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 174 Japan Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 175 Japan Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 176 Japan Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 177 Japan Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 178 India Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 179 India Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 180 India Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 181 India Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 182 India Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 183 India Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 184 South Korea Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 185 South Korea Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 186 South Korea Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 187 South Korea Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 188 South Korea Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 189 South Korea Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 190 Singapore Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 191 Singapore Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 192 Singapore Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 193 Singapore Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 194 Singapore Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 195 Singapore Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 196 Malaysia Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 197 Malaysia Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 198 Malaysia Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 199 Malaysia Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 200 Malaysia Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 201 Malaysia Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 202 Rest of Asia Pacific Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 203 Rest of Asia Pacific Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 204 Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 205 Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 206 Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 207 Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 208 LAMEA Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 209 LAMEA Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 210 LAMEA Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 211 LAMEA Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 212 LAMEA Lung Cancer Market by Country, 2017 - 2020, USD Million
TABLE 213 LAMEA Lung Cancer Market by Country, 2021 - 2027, USD Million
TABLE 214 LAMEA Bladder Cancer Market by Country, 2017 - 2020, USD Million
TABLE 215 LAMEA Bladder Cancer Market by Country, 2021 - 2027, USD Million
TABLE 216 LAMEA Melanoma Market by Country, 2017 - 2020, USD Million
TABLE 217 LAMEA Melanoma Market by Country, 2021 - 2027, USD Million
TABLE 218 LAMEA Hodgkin lymphoma Market by Country, 2017 - 2020, USD Million
TABLE 219 LAMEA Hodgkin lymphoma Market by Country, 2021 - 2027, USD Million
TABLE 220 LAMEA Other Application Market by Country, 2017 - 2020, USD Million
TABLE 221 LAMEA Other Application Market by Country, 2021 - 2027, USD Million
TABLE 222 LAMEA Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 223 LAMEA Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 224 LAMEA PD-1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 225 LAMEA PD-1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 226 LAMEA PD-L1 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 227 LAMEA PD-L1 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 228 LAMEA CTLA-4 Inhibitor Market by Country, 2017 - 2020, USD Million
TABLE 229 LAMEA CTLA-4 Inhibitor Market by Country, 2021 - 2027, USD Million
TABLE 230 LAMEA Immune Checkpoint Inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 231 LAMEA Immune Checkpoint Inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 232 Brazil Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 233 Brazil Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 234 Brazil Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 235 Brazil Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 236 Brazil Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 237 Brazil Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 238 Argentina Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 239 Argentina Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 240 Argentina Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 241 Argentina Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 242 Argentina Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 243 Argentina Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 244 UAE Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 245 UAE Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 246 UAE Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 247 UAE Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 248 UAE Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 249 UAE Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 250 Saudi Arabia Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 251 Saudi Arabia Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 252 Saudi Arabia Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 253 Saudi Arabia Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 254 Saudi Arabia Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 255 Saudi Arabia Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 256 South Africa Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 257 South Africa Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 258 South Africa Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 259 South Africa Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 260 South Africa Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 261 South Africa Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 262 Nigeria Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 263 Nigeria Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 264 Nigeria Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 265 Nigeria Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 266 Nigeria Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 267 Nigeria Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 268 Rest of LAMEA Immune Checkpoint Inhibitors Market, 2017 - 2020, USD Million
TABLE 269 Rest of LAMEA Immune Checkpoint Inhibitors Market, 2021 - 2027, USD Million
TABLE 270 Rest of LAMEA Immune Checkpoint Inhibitors Market by Application, 2017 - 2020, USD Million
TABLE 271 Rest of LAMEA Immune Checkpoint Inhibitors Market by Application, 2021 - 2027, USD Million
TABLE 272 Rest of LAMEA Immune Checkpoint Inhibitors Market by Type, 2017 - 2020, USD Million
TABLE 273 Rest of LAMEA Immune Checkpoint Inhibitors Market by Type, 2021 - 2027, USD Million
TABLE 274 KEY INFORMATION – ASTRAZENECA PLC
TABLE 275 KEY INFORMATION – BEIGENE LTD.
TABLE 276 KEY INFORMATION – SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
TABLE 277 KEY INFORMATION – BRISTOL MYERS SQUIBB COMPANY
TABLE 278 KEY INFORMATION – GLAXOSMITHKLINE PLC
TABLE 279 KEY INFORMATION – ELI LILLY AND COMPANY
TABLE 280 KEY INFORMATION – MERCK GROUP
TABLE 281 KEY INFORMATION – SANOFI S.A.
TABLE 282 KEY INFORMATION - MERCK & CO., INC.
TABLE 283 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.

List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 4 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, May – 2021, Dec) Leading Players
FIG 5 Recent strategies and developments: Sanofi s.a.